According to a new report North America Continuous Glucose Monitoring Device Market, published by KBV research, the North America Continuous Glucose Monitoring Device Market would witness market growth of 11.6% CAGR during the forecast period (2020-2026).
The US market dominated the North America Transmitters Market by Country in 2019, and would continue to be a dominant market till 2026; growing at a CAGR of 11.5 % during the forecast period. The Canada market is poised to grow at a CAGR of 13.9% during (2020 - 2026). Additionally, The Mexico market would witness a CAGR of 13.8% during (2020 - 2026).
The Homecare Settings market dominated the Canada Continuous Glucose Monitoring Device Market by End-user in 2019, growing at a CAGR of 12.7 % during the forecast period. The Hospitals market is experiencing a CAGR of 13.4% during (2020 - 2026). The Other End Users market is expected to witness a CAGR of 14.2% during (2020 - 2026).
The Sensors market dominated the Mexico Continuous Glucose Monitoring Device Market by Component in 2019, growing at a CAGR of 12.6 % during the forecast period. The Transmitters market would exhibit a CAGR of 13.8% during (2020 - 2026). Additionally, The Receivers market is showcasing highest CAGR of 14.3% during (2020 - 2026).
Report Structural Insights: https://www.kbvresearch.com/north-america-continuous-glucose-monitoring-device-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Abbott Laboratories, Medtronic PLC, F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, DexCom, Inc., Ypsomed AG, Senseonics Holdings, Inc., GlySens, Incorporated, A. Menarini Diagnostics Ltd. (The Menarini Group), Echo Therapeutics, Inc., Johnson and Johnson.
By Component
By End User
By Country
Companies Profiled
Unique Offerings from KBV Research
Unique Offerings 
